March 18, 2021

Mavrilimumab in Patients with Severe COVID-19 Pneumonia and Systemic Hyperinflammation (MASH-COVID): An Investigator Initiated, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• The monoclonal antibody treatment mavrilimumab did not significantly lower the proportion of patients with severe COVID-19 who were alive and off oxygen therapy at day 14 compared to placebo (52% vs 47%, OR = 1.48, 95% CI: 0.43-5.16) in a multicenter, double-blind placebo-controlled randomized trial (n=40). Patients were included in the study if they were hospitalized, had COVID-19 pneumonia, low blood oxygen levels, and a C-reactive protein concentration >5 mg/dL. Patients who were mechanically ventilated were excluded.

Cremer et al. (Mar 18, 2021). Mavrilimumab in Patients with Severe COVID-19 Pneumonia and Systemic Hyperinflammation (MASH-COVID): An Investigator Initiated, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial. The Lancet Rheumatology. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00070-9/fulltext